262 related articles for article (PubMed ID: 29635027)
1. The emerging role of copper-64 radiopharmaceuticals as cancer theranostics.
Boschi A; Martini P; Janevik-Ivanovska E; Duatti A
Drug Discov Today; 2018 Aug; 23(8):1489-1501. PubMed ID: 29635027
[TBL] [Abstract][Full Text] [Related]
2. Copper radiopharmaceuticals for theranostic applications.
Ahmedova A; Todorov B; Burdzhiev N; Goze C
Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
[TBL] [Abstract][Full Text] [Related]
3. Copper-64: a real theranostic agent.
Gutfilen B; Souza SA; Valentini G
Drug Des Devel Ther; 2018; 12():3235-3245. PubMed ID: 30323557
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.
Follacchio GA; De Feo MS; De Vincentis G; Monteleone F; Liberatore M
Curr Radiopharm; 2018; 11(1):22-33. PubMed ID: 29231149
[TBL] [Abstract][Full Text] [Related]
5. IAEA contribution to the development of 64Cu radiopharmaceuticals for theranostic applications.
Jalilian AR; Osso JA; Vera-Araujo J; Kumar V; Harris MJ; Gutfilen B; Guérin B; Li H; Zhuravlev F; Chakravarty R; Alirezapour B; Ávila-Rodríguez MA; Khan IU; Aljammaz I; Assaad T; Luurtsema G; Smith J; Duatti A
Q J Nucl Med Mol Imaging; 2020 Dec; 64(4):338-345. PubMed ID: 33026211
[TBL] [Abstract][Full Text] [Related]
6. [PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy].
Derlin T; Bengel FM
Pneumologie; 2017 Jan; 71(1):48-62. PubMed ID: 28114710
[No Abstract] [Full Text] [Related]
7. Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma.
Wachsmann J; Peng F
World J Gastroenterol; 2016 Jan; 22(1):221-31. PubMed ID: 26755872
[TBL] [Abstract][Full Text] [Related]
8. The development of copper radiopharmaceuticals for imaging and therapy.
Shokeen M; Wadas TJ
Med Chem; 2011 Sep; 7(5):413-29. PubMed ID: 21711219
[TBL] [Abstract][Full Text] [Related]
9. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide.
Hoffman TJ; Smith CJ
Nucl Med Biol; 2009 Aug; 36(6):579-85. PubMed ID: 19647163
[No Abstract] [Full Text] [Related]
10. Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.
Frier M
Mini Rev Med Chem; 2004 Jan; 4(1):61-8. PubMed ID: 14754444
[TBL] [Abstract][Full Text] [Related]
11.
Zhou Y; Li J; Xu X; Zhao M; Zhang B; Deng S; Wu Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819830758. PubMed ID: 30764737
[TBL] [Abstract][Full Text] [Related]
12.
Chakravarty R; Chakraborty S; Dash A
Mol Pharm; 2016 Nov; 13(11):3601-3612. PubMed ID: 27709959
[TBL] [Abstract][Full Text] [Related]
13. Production and purification of Scandium-47: A potential radioisotope for cancer theranostics.
Deilami-Nezhad L; Moghaddam-Banaem L; Sadeghi M; Asgari M
Appl Radiat Isot; 2016 Dec; 118():124-130. PubMed ID: 27640172
[TBL] [Abstract][Full Text] [Related]
14. Copper complexes of bis(thiosemicarbazones): from chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals.
Paterson BM; Donnelly PS
Chem Soc Rev; 2011 May; 40(5):3005-18. PubMed ID: 21409228
[TBL] [Abstract][Full Text] [Related]
15. Imaging of Prostate Cancer Using
Singh A; Kulkarni HR; Baum RP
PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
[TBL] [Abstract][Full Text] [Related]
16. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
17. (64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
Yoshii Y; Furukawa T; Matsumoto H; Yoshimoto M; Kiyono Y; Zhang MR; Fujibayashi Y; Saga T
Cancer Lett; 2016 Jun; 376(1):74-82. PubMed ID: 26996296
[TBL] [Abstract][Full Text] [Related]
18. Radiation protection in therapy with radiopharmaceuticals.
Hosono M
Int J Radiat Biol; 2019 Oct; 95(10):1427-1430. PubMed ID: 30265162
[No Abstract] [Full Text] [Related]
19. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
Morgan KA; Rudd SE; Noor A; Donnelly PS
Chem Rev; 2023 Oct; 123(20):12004-12035. PubMed ID: 37796539
[TBL] [Abstract][Full Text] [Related]
20. 67Cu-Radiolabeling of a multimeric RGD peptide for αVβ3 integrin-targeted radionuclide therapy: stability, therapeutic efficacy, and safety studies in mice.
Jin ZH; Furukawa T; Ohya T; Degardin M; Sugyo A; Tsuji AB; Fujibayashi Y; Zhang MR; Higashi T; Boturyn D; Dumy P; Saga T
Nucl Med Commun; 2017 Apr; 38(4):347-355. PubMed ID: 28291159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
